JAVELIN Renal 100: Phase 1b dose‐finding study of avelumab + axitinib in
1
st
line mRCC
JAVELIN Renal 100: Phase 1b dose‐finding study of avelumab + axitinib in
Larkin
et al
. ESMO 2016 Abstract 2513 Poster 775PD
1
st
line mRCC
−
Acceptable safety profile and encouraging clinical activity of the combination of avelumab 10
mg/kg IV Q2W + axitinib 5 mg orally BID continuously
•
All patients (6 of 6) in the study experienced a partial response with 5 of 6 responses ongoing at the
,
time of analysis
−
As of 13 Sept 2016, this study is ongoing and has enrolled 54 patients
These results support the rationale to further investigate efficacy and safety of combination
−
avelumab + axitinib vs current monotherapies for aRCC
•
A pivotal randomised phase 3 trial comparing avelumab + axitinib vs sunitinib was initiated in March
2016 (NCT02684006 [Motzer et al ESMO 2016: Abstract 1668])
.
